<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00469508</url>
  </required_header>
  <id_info>
    <org_study_id>P50DA018185-03</org_study_id>
    <secondary_id>P50DA018185</secondary_id>
    <nct_id>NCT00469508</nct_id>
    <nct_alias>NCT00462293</nct_alias>
  </id_info>
  <brief_title>Modafinil vs Placebo for the Treatment of Methamphetamine Dependence</brief_title>
  <acronym>Modafinil</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Evaluation of Modafinil vs Placebo for the Treatment of Methamphetamine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Modafinil is a non-amphetamine type stimulant that acts as a wakefulness-promoting drug, and
      is approved for managing symptoms of narcolepsy (i.e., daytime somnolence). Its precise
      mechanism of action in promoting wakefulness remains unclear. This trial is a
      placebo-controlled double-blind trial of modafinil, on a platform of contingency management
      (CM) and individual cognitive-behavioral (CBT) counseling, for the treatment of
      methamphetamine dependence. Participants in this study will complete a 2-week baseline
      screening period during which they will provide urine samples and complete physical and
      psychological assessments to establish their eligibility for the study. In addition,
      participants will be asked to provide a blood or saliva specimen for genetic testing in order
      to identify genetic variations that influence response to methamphetamine and to treatment
      with modafinil. Upon successful completion of screening, participants will be randomly
      assigned to receive either modafinil (400mg qd) or placebo during the 12 weeks of the study.
      Neither the participants nor study staff will know who is receiving active medication or
      placebo. Regardless of medication condition, all participants will receive CM and weekly
      individual CBT counseling sessions to help them stop using methamphetamine and prevent
      relapse. They will attend the clinical research site (either at the UCLA Hollywood Clinic, or
      the Rancho Cucamonga site) three times per week, providing urine samples at each visit,
      completing data measures, and receiving individual CBT counseling on one visit each week. At
      the end of the 12-week study, the medication or placebo will be discontinued. Participants
      will return to the research site approximately 30 days following medication discontinuation
      for a brief health check to assess any possible lingering side effects and complete brief
      data measures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This application proposes a placebo-controlled double-blind trial of modafinil, on a platform
      of contingency management (CM) and individual cognitive-behavioral counseling (CBT once
      weekly individual session), for the treatment of methamphetamine dependence. Modafinil is a
      medication warranting evaluation as a treatment for MA dependence. It has a half-life of
      approximately 15 hours and reaches steady state in 2-4 days (Package insert) and will likely
      require once daily dosing, which reduces problems with medication adherence. Modafinil has
      potent psychiatric and behavioral effects that include brightening mood (Menza et al., 2000;
      Ninan et al., 2004), improving cognition (Turner et al., 2004a, b; 2003), improving impulse
      control (Turner et al., 2003; Turner et al., 2004a), and countering fatigue (Beusterien et
      al., 1999, Stahl et al., 2003). These effects neatly counterbalance effects produced by MA
      withdrawal (Newton et al., 2004) and may have particular value in ameliorating the negative
      reinforcing properties of MA, i.e., when MA is used to immediately relieve depressed mood due
      to recent abstinence (Peck et al., 2005b). CM is a behavioral intervention that effectively
      helps substance abusers to initiate abstinence, particularly from cocaine (Higgins et al.,
      1993; Higgins et al., 2000; Higgins et al., 1991) and from methamphetamine (Roll &amp; Shoptaw,
      in press; Shoptaw et al., 2005). As well, CM has been shown to reduce substance abuse and
      optimize the effects of medications in reducing substance abuse (Carroll, 2004; Shoptaw et
      al., 2002). The objective of this study is to determine whether modafinil reduces
      methamphetamine use and concomitant physical and psychological symptoms more effectively than
      placebo when administered in conjunction with CM and CBT. The purpose of this project is to
      evaluate whether methamphetamine abusers seeking outpatient treatment demonstrate
      significantly significant reductions of methamphetamine when randomly assigned to receive
      modafinil (400mg qd) in combination with CM and weekly CBT compared their peers randomly
      assigned to receive placebo in combination with CM and weekly CBT.

      Research Hypotheses:

        1. Participants receiving active experimental drug (modafinil 400mg) will demonstrate
           statistically significant reductions in methamphetamine use over participants receiving
           placebo. Methamphetamine use outcomes will be measured using urine samples and analyzed
           with the following indices: Treatment Effectiveness Score, the Joint Probability Index,
           self-report of methamphetamine use verified by urine drug screening, and the longest
           uninterrupted period of methamphetamine abstinence. Primary analyses will be conducted
           using modeling approaches (Generalized Estimation Equations, Markov Chain Transition
           Models) depending upon the structure of the dataset. Self-report of methamphetamine use
           will be analyzed using the Addiction Severity Index drug composite scale and Substance
           Use Inventory (SUI).

        2. Participants receiving active experimental drug will remain in treatment for
           significantly longer periods compared to participants receiving placebo. Retention will
           be measured by the number of days in the protocol and analyzed using survival analysis.

           a. Specifically, participants with mild cognitive dysfunction (as measured as &lt;=1 SD
           below the published mean for the MicroCog assessments) receiving modafinil (400mg) will
           demonstrate significantly greater overall retention, and attendance to CBT sessions than
           those participants with cognitive function measured at greater than 1 SD below the mean
           for the MicroCog assessments who are receiving placebo.

        3. Participants receiving active experimental drug (modafinil 400mg) will demonstrate
           statistically significant reductions in reported methamphetamine craving over
           participants receiving placebo. Craving outcomes will be measured using a visual
           analogue scale.

        4. Participants receiving active experimental drug (modafinil 400mg) will demonstrate
           statistically significant reductions in withdrawal symptoms and somatic complaints
           compared to participants receiving placebo. These outcomes will be measured using the
           BSI, the Beck Depression Inventory-II, and the Quality of Well-Being scale.

      Exploratory analyses will also be conducted to identify potential genetic variants associated
      with treatment response to modafinil for MA dependence. Candidate genes implicated by
      previous research as being involved in the pathogenesis of MA dependence and/or the molecular
      mechanism of modafinil (for example, genes for neurotransmitter receptors and transporters,
      including dopamine, norepinephrine, GABA, and glutamate, as well as genes for enzymes
      involved in the metabolism of these neurotransmitter, such as catechol-O-methyltransferase
      and monoamine oxidase A) will be sequenced in order to determine the frequency of known
      single nucleotide polymorphisms (SNPs), as well as potentially identify novel SNPs, in these
      genes among MA dependent participants. Initial analyses will focus on genes involved in the
      dopaminergic pathway, given the importance of dopamine in the neurobiology of MA dependence,
      but additional genes may also be assessed. SNPs associated with response to modafinil will be
      identified in order to generate hypotheses for future pharmacogenomic studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clean Urine Drug Screen</measure>
    <time_frame>From randomization to end of week 12</time_frame>
    <description>Urine samples, collected thrice weekly, were tested for metabolites of MA using radioimmunoassay. Each subject had a possible of 36 urine drug screens to provide during the 12 weeks of medication. An aggregate measure of urine drug screen results was calculated - the Treatment Effectiveness Score (TES) - which is the average of the sum of MA-free urine specimens provided during the treatment period by participants in each treatment condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retention</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of persons who completed the medication phase of the trial (12 weeks of medication).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>VAS Score</measure>
    <time_frame>baseline and last observation during the 12 week treatment period</time_frame>
    <description>To measure methamphetamine craving, mean change in craving based on visual analog scale (VAS) from 0 (not at all) to 100 (extremely) from baseline to the last week of observation during the 12 week treatment period. The last observation was carried forward if not available during week 12.</description>
  </other_outcome>
  <other_outcome>
    <measure>BDI Score</measure>
    <time_frame>From baseline to end of treatment period (week 12).</time_frame>
    <description>Self-reported depression: mean change on Beck Depression Index (BDI-II) assessed weekly during the 12 week medication phase. If the week12 measure was not available, the last observation was carried forward. 0 indicates no depression, 63 is the maximum indicating severe depression.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Methamphetamine Dependence</condition>
  <arm_group>
    <arm_group_label>Modafinil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Modafinil 400mg oral dose taken daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Modafinil 0mg (sugar pill) oral dose taken daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <description>400mg pills taken orally daily for 12 wks.</description>
    <arm_group_label>Modafinil</arm_group_label>
    <other_name>Provigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>400mg pills taken orally daily for 12 wks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older;

          2. meet DSM-IV criteria for methamphetamine dependence;

          3. willing and able to comply with study procedures;

          4. willing and able to provide written informed consent;

          5. if female, not pregnant or lactating and willing to use an acceptable method of
             barrier birth control (e.g. condoms) during the trial and for one month after
             discontinuation of study medication (modafinil may reduce the effectiveness of
             steroidal contraceptives both during administration and for one month after
             discontinuation).

        Exclusion Criteria:

          1. have a medical condition that, in the study physician's judgment, may interfere with
             safe study participation (e.g., active TB, unstable cardiac, renal, or liver disease,
             unstable diabetes, or elevated liver enzymes (SGOT or SGPT) greater than 4 times the
             upper limit of normal);

          2. have a current neurological disorder (e.g., organic brain disease, dementia) or major
             psychiatric disorder not due to substance abuse (e.g., schizophrenia or bipolar
             illness) as assessed by the SCID and a medical history which would make study agent
             compliance difficult or which would compromise informed consent, or recent (past 30
             days) history of suicide attempts and/or current serious suicidal intention or plan as
             assessed by the SCID and the BDI-II;

          3. currently on prescription medication that is known to interact with the study drug;

          4. have current dependence on cocaine, opiates, alcohol, or benzodiazepines, as defined
             by DSM-IV-TR criteria;

          5. have a history of alcohol dependence within the past three years;

          6. have a history of mitral valve prolapse, left ventricular hypertrophy, cardiac
             arrhythmias, angina, myocardial infarction, acute coronary syndrome (unstable angina),
             cardiac syncope or presyncope, or any EKG abnormalities that suggests the presence of
             one of these conditions;

          7. have a systolic blood pressure greater than 160, a diastolic blood pressure greater
             than 100 (i.e. cutoffs for stage 2 hypertension), and a heart rate greater than 70% of
             the maximum heart rate expected for their age (0.70(220-age)) at any of the study
             visits.

          8. any other circumstances that, in the opinion of the investigators, would compromise
             participant safety;

          9. have a history of sensitivity to modafinil.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Shoptaw, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Vine Street Clinic</name>
      <address>
        <city>Hollywood</city>
        <state>California</state>
        <zip>90038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.uclasarx.org/</url>
    <description>Information about our research and group</description>
  </link>
  <results_reference>
    <citation>Heinzerling KG, Swanson AN, Kim S, Cederblom L, Moe A, Ling W, Shoptaw S. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2010 Jun 1;109(1-3):20-9. doi: 10.1016/j.drugalcdep.2009.11.023. Epub 2010 Jan 25.</citation>
    <PMID>20092966</PMID>
  </results_reference>
  <results_reference>
    <citation>Heinzerling KG, Shoptaw S. Gender, brain-derived neurotrophic factor Val66Met, and frequency of methamphetamine use. Gend Med. 2012 Apr;9(2):112-20. doi: 10.1016/j.genm.2012.02.005. Epub 2012 Mar 23.</citation>
    <PMID>22445683</PMID>
  </results_reference>
  <results_reference>
    <citation>Heinzerling KG, McCracken JT, Swanson AN, Ray LA, Shoptaw SJ. COMT Val158Met, BDNF Val66Met, and OPRM1 Asn40Asp and methamphetamine dependence treatment response: preliminary investigation. J Clin Psychopharmacol. 2012 Feb;32(1):135-7. doi: 10.1097/JCP.0b013e318240a48e.</citation>
    <PMID>22217949</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2007</study_first_posted>
  <results_first_submitted>December 7, 2012</results_first_submitted>
  <results_first_submitted_qc>February 13, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 15, 2013</results_first_posted>
  <last_update_submitted>February 13, 2013</last_update_submitted>
  <last_update_submitted_qc>February 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Steve Shoptaw</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Methamphetamine</keyword>
  <keyword>Modafinil</keyword>
  <keyword>Medication</keyword>
  <keyword>Contingency Management</keyword>
  <keyword>Crystal meth</keyword>
  <keyword>Los Angeles</keyword>
  <keyword>Addiction</keyword>
  <keyword>Meth</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were 71 MA-dependent outpatients seeking treatment in the Los Angeles area recruitment from 4/07-9/08. Potential study participants were recruited from the community using advertisements for a study of experimental medications for MA dependence.</recruitment_details>
      <pre_assignment_details>Subjects completed medical and psychiatric screening (to exclude any non-drug related Axis I disorder) and baseline assessments over a two-week/six-visit lead in.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Modafinil</title>
          <description>Modafinil 400mg oral dose taken daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Modafinil 0mg (sugar pill) oral dose taken daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Modafinil</title>
          <description>Modafinil 400mg oral dose taken daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Modafinil 0mg (sugar pill) oral dose taken daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.1" spread="11.1"/>
                    <measurement group_id="B2" value="37.8" spread="10.1"/>
                    <measurement group_id="B3" value="38.4" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clean Urine Drug Screen</title>
        <description>Urine samples, collected thrice weekly, were tested for metabolites of MA using radioimmunoassay. Each subject had a possible of 36 urine drug screens to provide during the 12 weeks of medication. An aggregate measure of urine drug screen results was calculated - the Treatment Effectiveness Score (TES) - which is the average of the sum of MA-free urine specimens provided during the treatment period by participants in each treatment condition.</description>
        <time_frame>From randomization to end of week 12</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil</title>
            <description>Modafinil 400mg oral dose taken daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Modafinil 0mg (sugar pill) oral dose taken daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clean Urine Drug Screen</title>
          <description>Urine samples, collected thrice weekly, were tested for metabolites of MA using radioimmunoassay. Each subject had a possible of 36 urine drug screens to provide during the 12 weeks of medication. An aggregate measure of urine drug screen results was calculated - the Treatment Effectiveness Score (TES) - which is the average of the sum of MA-free urine specimens provided during the treatment period by participants in each treatment condition.</description>
          <population>Intention to treat</population>
          <units>Clean urine drug screens</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Urine drug screens</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="590"/>
                <count group_id="O2" value="564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="11.5"/>
                    <measurement group_id="O2" value="12.7" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retention</title>
        <description>The number of persons who completed the medication phase of the trial (12 weeks of medication).</description>
        <time_frame>12 weeks</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil</title>
            <description>Modafinil 400mg oral dose taken daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Modafinil 0mg (sugar pill) oral dose taken daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Retention</title>
          <description>The number of persons who completed the medication phase of the trial (12 weeks of medication).</description>
          <population>Intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>VAS Score</title>
        <description>To measure methamphetamine craving, mean change in craving based on visual analog scale (VAS) from 0 (not at all) to 100 (extremely) from baseline to the last week of observation during the 12 week treatment period. The last observation was carried forward if not available during week 12.</description>
        <time_frame>baseline and last observation during the 12 week treatment period</time_frame>
        <population>Intention to treat, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil</title>
            <description>Modafinil 400mg oral dose taken daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Modafinil 0mg (sugar pill) oral dose taken daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Score</title>
          <description>To measure methamphetamine craving, mean change in craving based on visual analog scale (VAS) from 0 (not at all) to 100 (extremely) from baseline to the last week of observation during the 12 week treatment period. The last observation was carried forward if not available during week 12.</description>
          <population>Intention to treat, LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.5" spread="33.8"/>
                    <measurement group_id="O2" value="-47.3" spread="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>BDI Score</title>
        <description>Self-reported depression: mean change on Beck Depression Index (BDI-II) assessed weekly during the 12 week medication phase. If the week12 measure was not available, the last observation was carried forward. 0 indicates no depression, 63 is the maximum indicating severe depression.</description>
        <time_frame>From baseline to end of treatment period (week 12).</time_frame>
        <population>Intention to treat, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Modafinil</title>
            <description>Modafinil 400mg oral dose taken daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Modafinil 0mg (sugar pill) oral dose taken daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>BDI Score</title>
          <description>Self-reported depression: mean change on Beck Depression Index (BDI-II) assessed weekly during the 12 week medication phase. If the week12 measure was not available, the last observation was carried forward. 0 indicates no depression, 63 is the maximum indicating severe depression.</description>
          <population>Intention to treat, LOCF</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="12.9"/>
                    <measurement group_id="O2" value="-7" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were assessed at each study visit during the 12 weeks of treatment and in the follow up period (4 weeks).</time_frame>
      <desc>Subjects were questioned at each clinic visit about their general health. Any physical or clinical change or illness, whether or not considered study drug related, was recorded on the medical record chart and adverse event case report form.In case of an adverse event thought to reflect drug-related toxicity, evaluation and management ensued.</desc>
      <group_list>
        <group group_id="E1">
          <title>Modafinil</title>
          <description>Modafinil 400mg oral dose taken daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Modafinil 0mg (sugar pill) oral dose taken daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>COSTART</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <description>Not study drug related.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <description>Not study drug related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychosis</sub_title>
                <description>Not study drug related - MA induced</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Epididymitis</sub_title>
                <description>Not study drug related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>COSTART</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Heartbeats Increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Palpitation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Earache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Ears Feel Clogged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hearing decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Bowel Incontinena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>CHEST PAIN-L ARM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Chest tightness of</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Concentration Imparied</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Diaphoresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <description>Craving</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Head contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="34"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Herpes Simplex</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hyperactivity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="10" subjects_at_risk="34"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Jitterniness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Light-headed</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>MENTAL CONCENTRATION DIFFICULTY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nerve pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nightmares</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nosebleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Shakiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Sinus Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Tightness of chest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vivid Dreams</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Wakefulness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess Gum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Infection Upper Respiratory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Tinea</sub_title>
                <description>Ringworm</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Ache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Leg cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pain muscle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pain neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Delusions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hallucitation Auditory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>GENITALIA EXTERNAL PAINFUL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Libido Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Common Cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Congestion Nasal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Coughing</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Sexual Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Rash Impetiginous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Fracture Bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>study is powered to detect at least a moderate effect for modafinil (d = 0.50) in the overall sample; subgroups may be more meaningful</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Steven Shoptaw PhD</name_or_title>
      <organization>UCLA Center for Behavioral and Addiction Medicine</organization>
      <phone>310 794 0619 ext 225</phone>
      <email>sshoptaw@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

